header-logo header-logo

Home Login E-newsletter About us
06 November 2015
Issue: 7675 / Categories: Case law , Law digest , In Court
printer mail-detail

Patent

© Copyright LexisNexis 2026. All Rights Reserved.

Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG [2015] EWHC 2963 (Pat), [2015] All ER (D) 214 (Oct)

The Chancery Division held that an application brought by the defendant pharmaceutical company, Boehringer Ingelheim Pharma GmbH & Co KG, to introduce new claims to a patent dispute would be dismissed, where the proposed use of a drug, to be used in a dry powder inhaler for the delivery of tiotropium bromide to the lung of a patient suffering from chronic obstructive pulmonary disease or asthma, was obvious and the new claims revealed no inventive step.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Read All
Sponsored by
TheGazette LogoClick to know more
Carter-Ruck—Tomas Vail

Carter-Ruck—Tomas Vail

Carter-Ruck strengthens International team with appointment of arbitration partner Tomas Vail

Slater Heelis—Nick Terry

Slater Heelis—Nick Terry

Slater Heelis strengthens crime and regulatory team with appointment of Nick Terry as partner

Payne Hicks Beach—Thomas Moran & Sarah Gogan

Payne Hicks Beach—Thomas Moran & Sarah Gogan

Payne Hicks Beach strengthens private wealth offering with appointment of two new partners

NEWS
Read All
NLJ this week: Same fall, different claim
Construction workers injured in comparable accidents can face sharply different routes to compensation on opposite sides of the Atlantic
NLJ this week: Under pressure? Routes to redress
Victims of undue influence may have more options than simply unwinding a tainted transaction, with courts able to order profits accounts, compensation and, exceptionally, severance
NLJ this week: Liberty safeguards under strain
Disabled people could lose vital safeguards following the Supreme Court’s reversal of the Cheshire West test for deprivation of liberty, two barristers warn
NLJ this week: When partners lose faith
A formidable reputation cannot protect a law firm when partner departures, fragile finances and client uncertainty begin feeding each other
NLJ this week: The hidden price of free software
Businesses incorporating open-source software into commercial products could face obligations to disclose valuable source code, with AI-assisted development making licensing risks harder to track
Copyright © 2026 LexisNexis
back-to-top-scroll